http://orcid.org/0000-0002-3281-2316
Figures
Abstract
Africa is the second most populous continent and has perennial health challenges. Of the estimated 181 million school aged children in sub-Saharan Africa (SSA), nearly half suffer from ascariasis, trichuriasis, or a combination of these infections. Coupled with these is the problem of tuberculosis (TB) caused by Mycobacterium tuberculosis (Mtb) infection, which is a leading cause of death in the region. Compared to the effect of the human immunodeficiency virus on the development of TB, the effect of chronic helminth infections is a neglected area of research, yet helminth infections are as ubiquitous as they are varied and may potentially have profound effects upon host immunity, particularly as it relates to TB infection, diagnosis, and vaccination. Protection against active TB is known to require a clearly delineated T-helper type 1 (Th1) response, while helminths induce a strong opposing Th2 and immune-regulatory host response. This Review highlights the potential challenges of helminth–TB co-infection in Africa and the need for further research.
Citation: Cadmus SI, Akinseye VO, Taiwo BO, Pinelli EO, van Soolingen D, Rhodes SG (2020) Interactions between helminths and tuberculosis infections: Implications for tuberculosis diagnosis and vaccination in Africa. PLoS Negl Trop Dis 14(6): e0008069. https://doi.org/10.1371/journal.pntd.0008069
Editor: Susanna Jane Dunachie, University of Oxford, UNITED KINGDOM
Published: June 4, 2020
Copyright: © 2020 Cadmus et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: The authors received no specific funding for this work.
Competing interests: The authors have declared that no competing interests exist.
Introduction
Africa, with approximately one billion residents, is the second most populous continent and accounts for about 15% of the world's population [1]. As a result of factors beyond the scope of this Review, the continent carries a disproportionate burden of infectious diseases, such as human immunodeficiency virus (HIV), malaria, and tuberculosis (TB) [2]. TB is the leading cause of mortality in sub-Saharan Africa (SSA), with 29% of the 9 million TB cases occurring there in 2013 and 254,000 TB-related deaths [3]. Helminth infections are also highly prevalent with the soil-transmitted helminth (STH) infections, which account for about 85% of the neglected tropical diseases (NTDs) affecting sub-Saharan Africans [4]. Helminth infections are chronic diseases and typically cause asymptomatic infection or prolonged morbidity rather than mortality [5].
Co-endemicity of helminths and other infections in SSA has consequences for public health and affected hosts. Much is already known about the bidirectional interaction of Mtb and HIV; however, there is relatively sparse understanding of the interaction between Mtb and helminth infections—the subject of this Review in the context of Africa—and existing data on the potential immunologic consequences, including those that may affect TB vaccination and diagnosis. This Review supports the need for studies to clarify the impact of helminth co-infection on TB control and how any negative impact might be mitigated, as highlighted by the World Health Organization (WHO) in 2012 in its published top-ten list of research priorities for helminth infections [6].
Methods
A systematic search was conducted using Google Scholar, Pubmed, CAB Direct, and African Journals Online (AJOL), using the following search words and phrases: helmint*, tubercul*, helmint* and tubercul*, helminth and tuberculosis infection Africa, helminth and tuberculosis diagnos*, and helminth and tuberculosis vaccin*. The review included studies involving helminth, TB, and helminth–TB infection, diagnosis, and vaccination in humans and animals.
The burden of helminth infection in Africa
Helminths are multicellular worms that belong to three taxonomic groups: cestode (tapeworms), nematode (roundworms), and trematode (flukes). They present a striking variety of life cycles, from direct fecal–oral transmission (ingestion of worm eggs, e.g., of the roundworms Ascaris lumbricoides and Trichuris trichiura) to development through free-living stages (larval penetration of the skin, e.g., from Ancylostoma duodenale hookworm) or dependence on invertebrate vectors (such as the schistosome snail vector). Helminths may also infect via insect bite, for example, from the filarial worms Onchocerca (blackfly) and Brugia species (mosquito). In SSA, the most common helminth infections are hookworms, followed by schistosomes, ascarids, Trichuris whipworms, and lymphatic filariasis (Brugia) (Table 1) [7–10].
In the vast majority of developing tropical and subtropical regions of the world, helminth infections, especially those caused by STHs and schistosomes, constitute major public health challenges, particularly among school aged children who may be nutritionally or physically impaired as a result [10–12]. Current WHO estimates indicate that about 1.5 billion individuals are infected with STH infections globally (https://www.who.int/news-room/fact-sheets/detail/soil-transmitted-helminth-infections), with more than one-half of SSA’s population affected by one or more helminth infections [12,13] Of the estimated 181 million school-aged children in SSA, almost one-half (89 million) are infected with hookworm, ascariasis, trichuriasis, or some combination of these STH infections, which may vary according to factors such as geographical location and socioeconomic status within a given country and even the type of school attended [4, 10–14]. The disability-adjusted life years (DALYs) lost due to these helminth infections provide a more accurate picture of the disease burden, although the estimates of DALYs lost differ greatly from one source to another (Table 1) [15].
The conventional control programs for helminths are based on mass treatment, as recommended by WHO (2017 Guideline: Preventative Chemotherapy to Control STH Infections in At-Risk Population Groups). Regular treatments with broad-spectrum antihelminth drugs (such as the benzimidazoles, mebendazole, or albendazole) are effective at reducing morbidity from STH infections and are well-tolerated, while ivermectin has been employed in areas endemic for filarial diseases. In the case of ivermectin treatment of filariasis in Africa, while progress is being made (e.g., a recent report from Sierra Leone described reductions in Onchocerca worm burden [16]), in other countries and areas issues such as poor medicine distribution (e.g., one study in Nigeria [17]) and treatment side effects (e.g, increased epilepsy cases in Tanzania [18]) also need to be addressed if elimination of these debilitating parasites is to be achieved. Even so, a meta-analysis of helminth re-infection studies has shown that prevalence can be quick to re-establish—in this case Ascaris, Trichuris, and hookworms re-established over the ensuing 12 months to 94%, 82%, and 57% of pretreatment levels, respectively [19]. According to the opinion of some experts, treatment of infected individuals, even on a mass scale of drug administration, is not itself sufficient to resolve issues that are fueled by poverty, lack of sanitation, adequate hygiene, and education [20]. Access to a clean water supply to wash fruit and vegetables, identified as an important risk factor particularly in rural areas of Africa [21], could reduce the DALYs lost via such food-borne infection routes [22], supporting the critical role of access to clean water supplies, environmental sanitation, and also education as important to break transmission routes while other potential control measures, such as the use of vaccines are theoretically attractive but remain elusive.
TB in Africa
TB is a chronic debilitating and wasting disease resulting from infection with Mtb and remains among the leading causes of death from an infectious agent globally. About 5% to 10% of infected humans develop active TB within one year of infection (primary TB). The remainder are classified as individuals with latent TB infection (LTBI). About 5% to 10% of latently infected individuals develop clinical TB during their lifetime via reactivation. Others develop active TB after re-infection with Mtb because LTBI does not provide full immunity against repeated infection [23–24]. Whether or when a latently infected person will develop active TB is summed up by Comstock and colleagues [25]: “Following infection, the incubation period of TB ranges from a few weeks to a lifetime. Both the length and variability of the incubation period are tremendously greater than for nearly all other infectious diseases,” making TB a disease of significant public health importance.
Since the 1990s, TB incidence rates in different parts of the world have developed quite divergently. TB is a major cause of ill health and death, mainly in Africa and Asia where factors like poverty, malnutrition, overcrowding, HIV, poor living conditions, and, of recent, development and spread of multidrug resistant TB are fueling the epidemic. In 2016, the estimated global TB incidence rate was 140 cases per 100,000 persons, which equates to 10.4 million (range of 8.8 to 12.2 million) incident TB cases. Most of the estimated incident TB cases in 2016 were in Southeast Asia (45%) and Africa (25%), with smaller proportions of cases in the Eastern Mediterranean region (7%), Europe (3%), and the Americas (3%) [26]. Whereas in most parts of the world TB incidence rates remained stable or have declined slightly, in Africa, the incidence rates have increased by almost 30%. This increase was most pronounced in the southern half of the continent, especially South Africa, where the incidence nearly quadrupled to approximately 1,000 cases per 100,000 persons.
Bacille Calmette Guerin (BCG), an attenuated strain of Mycobacterium bovis, was first used to vaccinate humans against TB in 1921. This vaccine is estimated to provide about 73% protection against fatal forms of childhood TB but shows inconsistent efficacy (with a protection that varies from 0% to 80%) against development and transmission of adult TB [27]. This, coupled with the rising TB epidemic worldwide, compelled WHO to declare TB a global emergency in 1993 [28]. Progress in controlling TB has been slow, and epidemiological models have suggested that global TB elimination targets can only be achieved with a combination of effective TB vaccination, diagnosis, and treatment strategies [29–30]. However, we suggest that included within this strategy must be consideration for those ubiquitous helminth species that have co-evolved with humans and TB and have the potential to undermine TB control by diverting the host immune responses upon which host protection and TB diagnostic tests rely. A better understanding of the effects of helminths on these key interventions may uncover mediating pathways that can be exploited to accelerate the attainment of global TB elimination goals
Potential impact of helminths on host responses to TB infection, vaccination, and diagnosis
Containment of Mtb by the immune system
Upon inhalation of Mtb bacilli, the alveolar macrophages are among the first cells to encounter the micro-organism (Fig 1), making macrophages the first line of defense against invading Mtb. Bacilli become trapped inside a vacuole called phagosome, which thereafter undergoes sequential fusion to acquire microbicidal and degrading characteristics by a process called maturation, which is regulated by the network of Rat sarcoma (Ras) associated binding Guanosine Triphophatases (Rab GTPases), proteins that drive the phagosome progression to maturation [31]. Despite the potential of activated macrophages to kill pathogens, the bacilli can escape this fate and survive within the host macrophage through mediation of pathogen-dependent inhibition of phagosome-lysosome fusion, thus helping it to persist within the immature phagosomal compartment [32]. Further, it was shown that some Mtb strains that were poorly adapted within endocytic vesicles of infected macrophages, through activation of host cytosolic phospholipase A2, rapidly escaped from phagosomes and established residence in the cytoplasm of the host cell, thus creating an alternative survival path for Mtb within the host macrophage [33].
IL, interleukin; TH1, T-helper type 1; TGF-β, transforming growth factor β; TNF-α, tumor necrosis factor-alpha.
Mtb antigen presentation by dendritic cells, potentially aided by neutrophils, in the draining lymph nodes induces a local immune response that results in the recruitment of various cell types to the site of infection, including monocytes, macrophages, neutrophils, and dendritic cells. Together, these cells form a primary granuloma, which, while enclosing the infection, may also permit Mtb growth until T cells are recruited to the infection site (Fig 1) [34]. Protection against active TB is known to require a clearly delineated T-helper type 1 (Th1) response, mediated by interferon-gamma (IFNγ), interleukin-2 (IL2), and tumor necrosis factor-alpha (TNFα) [35–37], which may clear infection or drive it into an immune-mediated containment or latency. Th1 cell responses play a role in the proinflammatory functions necessary for the development of cell-mediated immune responses [38]. IFNγ may also act on cells other than macrophages, and one important function may be to limit polymorphonuclear cell (PMN)-driven inflammation [39]. Mouse models have shown that most susceptible mouse strains exhibit high PMN infiltration in the lungs once infected [40–42], and inhibition of this infiltration improves survival. However, mice that lack IFNγ exhibit high PMN infiltration compared to those lacking cluster of differentiation (CD)4+ T cells.
Humans deficient in the production of Th1-type cytokines like IFNγ and its receptor are also known to be susceptible to fulminant mycobacterial infections, including Mtb [42]. IFNγ has been shown to be important in macrophage activation with the resulting stimulation of, for example, nitric oxide synthase and L-arginase production [43–44] and vitamin-D–dependent autophagy, phagolysosome fusion, and bacterial cell death [45].
Immune responses to helminths and Mtb
Helminths induce a strong Th2 host response that promotes, for example, mucus secretion, collagen deposition, and wound healing mechanisms that are critical for helminth expulsion. Yet despite the induction of such protective Th2 responses, helminths often persist in the host, resulting in chronic infection [46]. Persistence is achieved, in part, by the induction of immunoregulatory pathways that are favorable to helminth survival. Among the immunoregulatory cells induced during chronic helminth infection, regulatory T cells (Tregs) producing cytokines such as transforming growth factor β (TGFβ) and interleukin 10 (IL-10) have been well documented (Fig 1). This expanded population of Tregs can down-modulate both Th1 and Th2 inflammatory responses and interfere with their effector T-cell functions [47–51, 52]. Not surprisingly therefore, prolonged exposure to parasitic helminth infection has been associated with generalized immune hyporesponsiveness [53]. Th2, Tregs, and the immunoregulatory cytokines they produce (such as interleukin-4 [IL4], IL10, and TGFβ) generated during helminth infection may act as potent inhibitors of the Th1 responses which are required for immunity against Mtb infection [54–55] (Fig 1).
Reactivation of LTBI and severity of active TB
In humans, endogenous reactivation of LTBI has been associated with increased production of IL10 and TGFβ by circulating monocytes and possibly Tregs [56] and also with the inhibition of proinflammatory TNFα, for example, in patients treated with TNFα antagonists for other conditions [57]. Studies have also shown that in patients with LTBI, co-infection with helminths (filariae and hookworms) can induce down regulatory roles on the protective Th1 and Th17 responses required for the control of Mtb infection in LTBI, potentially predisposing towards the development of active disease [58–60]. In the case of filarial infection, this effect may be mediated by both the cytotoxic T lymphocyte antigen (CTLA)–4 and programmed death (PD)–1, with resulting down-regulation of the Th1 proinflammatory cytokines IFNγ, IL-17, IL-12, and IL-23 and restored following antifilarial chemotherapy [59, 61]. However, studies investigating co-existing helminth infection and prevalence of active TB can differ in their conclusions, with one study in Ethiopia showing a doubled risk of active TB in intestinal helminth coinfected individuals [62], while another larger study of intestinal and filarial helminths in India suggested little effect on progression from latent to active pulmonary TB [63].
Experimental rodent models have examined whether helminth co-infection can exacerbate TB pathology. Cotton rats, a natural host for the filarial nematode Litomosoides sigmodontis, coinfected with Mtb showed no greater granulomatous inflammation or bacterial burden in the lung when compared to Mtb-only infected animals [64]. Whether this lack of TB exacerbation was due to the induction of regulatory cells and cytokines in this model was not investigated; however, it was noted that the IFNγ responses to tuberculin purified protein derivative (PPD) were the same in Mtb-only and helminth-Mtb coinfected rats. As natural hosts for L. sigmodontis, it is possible that cotton rats have evolved immune-regulatory pathways that mitigate the effects of this helminth. Overall, the association between helminth infections and immunosuppression is complex since several factors may determine whether infection with the parasite suppresses, exacerbates, or has no effect on immune responses to other infections or unrelated antigens. These factors include the species of the helminth, the parasite load, and whether the host is experiencing a recent or a chronic infection [65].
BCG immunogenicity
BCG is the most widely used vaccine worldwide and is the only registered vaccine available against TB and leprosy [66–67]. Nevertheless, it has a highly variable efficacy (from 0% to 80%) against pulmonary TB [27], and its protection against this disease has been hypothesized to wane due to gradual attrition of mycobacteria-specific T cells [68]. While BCG vaccination of newborns and infants significantly reduces the risk of childhood complications of TB, because the infant immune system is immature [69–71], it shows a bias towards Th2 cell polarization and low cytokine production, compared with those of adults. BCG vaccination generally induces strong Th1 cell responses, while the degree and quality of these responses vary in different settings [72–74].
Where helminth infection is endemic, particularly in SSA, the newborn is further primed immunologically in utero by its mother to helminth antigens with resultant effect of immunological bias towards Th2 and/or immunoregulatory responses—another route by which helminth infection can ultimately culminate in a reduced immunogenicity of the BCG vaccine [75] and negatively impact upon vaccination programs designed to boost BCG-vaccine-induced immunity. It is known that young children in the United Kingdom and Malawi responded differently to BCG vaccination, with a differential expression of Th1 and Th2 cytokines, respectively, and smaller BCG scars in Malawian infants [76–77]. Whether there was a helminth component acting here was not investigated.
TB vaccines other than BCG are also potentially at risk of helminth-associated reductions in efficacy. The modified vaccinia Ankara virus expressing the immunodominant mycobacterial antigen 85A (MVA85A) is known to induce strong durable Th1 memory cells in adults but only modest cell-mediated immune responses in infants [78–79]. Exploration of the effect of concurrent schistosome infection on the BCG-boosting immunogenicity of the MVA85A vaccine in adolescents [80], however, suggested no detrimental effect of helminth co-infection in these individuals. More recently, vaccine protection against active TB in latently infected adults from South Africa, Kenya, and Zambia has been reported using another subunit vaccine M72/AS01E [81]. It would be nice to think that any further trials to expand this promising data would give some attention to the immune preconditioning that can result from helminth infection.
That a reduced skin test conversion rate following BCG vaccination can result from helminth co-infection was described in 1989 by Kilian and Nielsen [82] in children with onchocerciasis where 45% of helminth-infected children showed vaccine responses, compared to 85% in controls. A later randomized trial showed a lower BCG immunogenicity in individuals with untreated helminth infection compared to infected individuals who received antihelminthic therapy [83]. The reduced responses were associated with a reduced tuberculin PPD-specific interferon gamma (IFN-γ) and IL-12 production and increased PPD-specific TGF-β rather than an increased PPD-specific Th2 profile per se. Similarly, 18-to-24-year-old helminth-infected college students in Ethiopia who were dewormed before BCG vaccination had improved specific immune responses to PPD compared to those who were not dewormed [84].
Immunological imprinting of in utero helminth exposure can affect BCG responses later in life, as has been shown in neonates who received BCG vaccination within 24 hours of birth in rural Kenya, with differing responses to PPD at 10 to 14 months of age; children with in utero sensitization to Wuchereria bancrofti or Schistosoma haematobium produced a 26-fold lower PPD-specific IFNγ compared to those whose cord blood lymphocytes showed no evidence of in utero sensitization to these two helminths [85]. However, the antenatal treatment of pregnant women in an area of low helminth prevalence with anthelmintic was shown to have no effect upon the subsequent cellular responses of their children to BCG vaccination [86], suggesting perhaps that the benefit of anthelmintic treatment to BCG vaccine efficacy is mainly to be found where helminth burden is sufficiently high as to interfere with vaccine responses in the first instance. Since much helminth diagnostic testing relies upon low sensitivity methods, like egg counts, this at least provides some confidence that those populations most in need of deworming (high worm infections) would be identifiable using current methods.
Previous studies of revaccination with BCG in order to boost vaccine efficacy had been conflicting, leading WHO to conclude in 1995 that there is no definitive evidence that repeated BCG vaccination confers additional protection against TB [87]. However, a recent trial to assess the efficacy of BCG revaccination versus the candidate TB subunit vaccine H4:IC31 in Cape Town, South Africa [88] has shown both vaccines to reduce transmission (as measured by sustained IFN-γ conversion), with BCG revaccination potentially having the edge. Again, some consideration of preexisting helminth infection as part of such vaccination trials could add value, especially when rolled out to the more rural areas where helminth infection of vaccine recipients might be expected to be higher than in Cape Town.
Exposure to environmental mycobacteria—which like helminths is also considered as higher in rural communities and developing countries—has long been suspected of affecting BCG vaccine efficacy; a review of randomized controlled trials concluded that a higher BCG efficacy was associated with the absence of sensitization with environmental mycobacteria, these geographical areas being further from the equator [89–90]. While meta-analysis has supported a greater BCG vaccine efficacy further away from the equator, it highlighted a number of factors, including environmental mycobacteria, socioeconomic conditions, and nutrition, that could be important [90–91]. Coincidentally, malnutrition may of course be helminth induced. A study of randomly selected adults in Peru showed that protein malnutrition correlated with a higher risk of a false-negative tuberculin skin test result [92]. Even among Canadians, malnutrition was found to be a major risk factor for developing TB [93]. Other possible contributors to the inconsistency of BCG efficacy include (1) genetic or physiological differences among study populations and/or differences in Mtb strains within the populations; (2) strain variation in BCG preparations [94], with strong evidence [95] that genomic differences in BCG strains will ultimately affect the potency of the strain used in a given setting, and (3) the method of preparation itself (e.g., the type of culture medium used to grow vaccine stocks has been shown to influence the later survival of BCG in host cells and the generation of host protective immunity [96]). Overall, then, helminth infection appears to be one of several factors that may compromise the efficacy of BCG vaccination, and this highlights the importance of carefully designed studies to untangle this complex web of observed associations.
TB diagnosis
Similar to the induction of TB vaccination responses, methods for detecting subclinical TB infection using the tuberculin PPD skin test or the more recent blood IFN-γ tests require a functional host immune response. Thus, modulation of immune responses caused by concurrent helminth infection may reduce the reliability of TB diagnosis. Consistent with this, Stewart and colleagues [97] reported an association between onchocerciasis skin microfilariae density and the down-modulation of cellular responses to PPD plus an age-related skewing of the immune response towards a Th2 profile.
Studies of M. bovis infection in cattle, a natural host–pathogen relationship, similarly highlight helminth infection as a potential confounder of TB diagnostics. Claridge and colleagues (2014) [98] estimated that exposure to the common fluke Fasciola hepatica in dairy herds across England and Wales could be contributing to a reduced diagnosis of M. bovis infection due to the negative effect of this helminth upon the PPD skin test and a reduced Th1 response in high fluke prevalence areas. However, it was also found that naturally coinfected cattle carried a reduced burden of M. bovis with an associated suppression of proinflammatory cytokines [99]. Therefore, while helminth co-infection may result in a reduced immune-diagnosis of infected individuals, those individuals could, in fact, pose a lower clinical and TB transmission risk owing to a helminth-driven reduction in bacillary burden. There are clinical co-infection studies that support such a view. Mhimbira and colleagues [100] described a significantly lower sputum bacterial load and lung cavitation among active TB patients in Tanzania coinfected with the blood fluke S. mansoni compared to those without helminth co-infection. Similarly, Abate and colleagues [101] found that concomitant asymptomatic helminth infection of TB patients in Ethiopia resulted in a lower sputum smear positivity together with an increase in regulatory and Th2 immune responses, a situation that was reversed by antihelminthic drug administration. In both of these studies helminth-driven reductions in sputum bacilli, potentially reflecting an improved host TB infection status (e.g., reduced lung cavitation in Mhimbra and colleagues), at the same time risks a reduction in the sensitivity of TB diagnosis and a subsequent delay in treatment. This would also be a consideration for other tests reliant upon sputum bacillary load such as the XpertMTB/RIF polymerase chain reaction, which has been shown to correlate with sputum smear counts [102].
That helminth-infected individuals might be able to control or modulate their Mtb infection was recently reported in a study of Nepalese immigrants to the UK [103]. In this study, a significant negative association was apparent between hookworm (Strongyloides) infection and latent TB (as identified by positive IFN-γ responses). Importantly, this study further demonstrated that blood from hookworm-infected individuals could control the growth of virulent Mtb in vitro, and this control was lost following anthelmintic treatment.
The use of IFNγ release assays (IGRAs) for TB diagnosis has grown in recent years [104–105]. These tests (e.g., QuantiFERON-TB Gold, Cellestis Ltd., Australia and T-SPOT.TB, Oxford Immunotec Ltd., UK) are widely regarded as more sensitive and specific than the skin test and use specific antigens such as ESAT6 and CFP10 that are present in Mtb and M. bovis but deleted from the M. bovis BCG vaccine strain [106]. Studies have shown that helminth infection can reduce IFN-γ production in response to mycobacterial infection, for example, above in cattle and in Bangladesh children and pregnant Ethiopian mothers [107–108], risking TB diagnostic sensitivity. However, a recent study of latent TB patients co-infected with hookworm shows that reduced TB-specific IFN-γ responses can be reversed following treatment with anthelmintic [109].
There is evidence to suggest that helminth co-infection does not always have a negative impact on TB immune responses. A study of Amerindians in Venezuela suggested a positive correlation between helminth (Ascaris and Trichuris) infection and PPD skin test–positivity in household contacts of sputum smear–positive patients [110]. And while a cross sectional study in southern India found no significant association between frequencies of PPD skin test positivity and intestinal helminth or filarial infection, BCG vaccination responses were associated with a lower prevalence of hookworm infection in this study [111]. This highlights the importance of research to understand helminth–TB relationships in a given situation to avoid the danger of assuming that one size will fit all.
Conflicting issues requiring clarity?
Due to the sometimes-apparent conflicting evidence that helminth co-infection may or may not affect Mtb infection, vaccination, and diagnosis (see Table 2), overall clarity on the consideration of helminth co-infections in TB vaccination and control programs could be timely. Pertinently, at a clinical level, should deworming prior to TB vaccination represent best practice in getting the most effective vaccine response, generating a “window of opportunity” to allow an effective Th1 memory, and for which populations of vaccine recipients (by age, community or area of helminth burden?) and against which specific helminth infections would this be most relevant and beneficial? Indeed, are helminth co-infections a potentially wider issue (i.e., than TB) that could be affecting vaccine success in general [112]?
At a more fundamental research level, the conflicting scenarios presented by different studies may not be unrelated to the fact that antigens from different helminth species cause different responses towards Mtb within host macrophages [113]—with the effect of either enhancing or diminishing the bactericidal function of macrophages and potentially priming the downstream adaptive immune response, such as the recently described DNA methylation of CD4+ T cells that appears to be helminth-specific [114]. Based upon these, important initial interactions could result an increased mycobacterial burden [115–116], a reduction [116–118], or have no effect [119]. Therefore helminth-driven skewing of the earliest immune responses to mycobacterial infection in the long term could provide novel interventions of immense potential future value.
Conclusion
Immunity to TB depends upon a protective Th1 response, which may be subverted by parasitic helminths that are biased towards inducing opposing Th2 responses. Furthermore, the chronic nature of helminth infections also invoke immune-regulatory responses that can reduce TB immunity and interfere with induced diagnostic responses upon which TB control programs depend. Since there is widespread helminth co-infection in areas of high TB incidence in Africa, the immunomodulation engendered by these common but different helminth infections may be a critical determinant for host immunity to TB, diagnostic tests, and the efficacy of preventive vaccines. The impact of these co-evolved microbial and parasitic interactions on the strategies required for optimal public health would appear daunting, particularly considering the apparent complexity and conflicting outcomes in disparate helminth–TB co-infection studies. However, there is the tantalizing potential for improvement in our diagnostic and vaccination outcomes by addressing this relatively neglected component of host TB immunology.
Key learning points
- Africa is characterized by plethora of problems including poverty, poor hygiene, and sanitation, which are exacerbated by infectious diseases and weak health systems. Unfortunately, these problems are also worsened by an overlapping burden of helminth and TB co-infection with far reaching public health implications, though currently attracting little attention.
- There are contradictory reports of differences in the population responses to BCG vaccination. However, reports abound that helminth-specific immune responses acquired during gestation persisted into childhood. Thus, the prenatal sensitization induced by helminths, biases the T cell immunity away from Th1 IFN-γ responses associated with protection against mycobacterial infection.
- There are existing reports on the negative impact of helminthes on TB diagnosis. This becomes important where asymptomatic helminth infection profoundly affects the immune phenotype of TB patients with a strong bias towards Th2 types of immune response, such as increased regulatory T cells as well as IL-5 and IL-10 secreting cells.
- There are increasing challenges that helminth–TB co-infection are also found to be associated with a significantly lower ratio of sputum smear positivity, which correlates with the egg load in helminth positive TB patients. This is of great public health importance in areas of the world, particularly Africa, where the burden of TB is high coupled with poor diagnostic facilities.
- The association between helminth infections and immunosuppression is complex since several factors may determine whether infection with the parasite suppresses, exacerbates, or has no effect on immune responses towards TB. These includes the species of helminths, the parasite load, and whether the human host is experiencing a recent or a chronic infection. These are critical issues that need further investigations in resolving the complex challenges posed by helminth–TB co-infection regarding diagnosis, treatment, and vaccination strategies in tuberculosis. The prevalent helminth co-infection in areas of high TB incidence in Africa remains an important factor that will determine the immunomodulation caused by the common but different helminth infections towards host immunity to TB, diagnostic tests, and the efficacy of preventive vaccines. Moving forward, it will be important to confirm if prior deworming to TB vaccination imply best practice in achieving optimal vaccine response, and for which helminth infections and human population groups would this be useful?
Top five papers
- Babu S, Bhat SQ, Kumar NP, Jayantasri S, Rukmani S, Kumaran P et al. Human type 1 and 17 responses in latent tuberculosis are modulated by coincident filarial infection through cytotoxic T lymphocyte antigen–4 and programmed death–1. J Infect Dis. 2009; 200:288–298.
- Elias D, Britton S, Aseffa A, Engers H, Akuffo H. Poor immunogenicity of BCG in helminth infected population is associated with increased in vitro TGF-beta production. Vaccine. 2008; 26(31):3897–902. doi: 10.1016/j.vaccine.2008.04.083.
- Aira N, Andersson AM, Singh SK, McKay DM, Blomgran R. Species dependent impact of helminth-derived antigens on human macrophages infected with Mycobacteriumtuberculosis: Direct effect on the innate antimycobacterial response. PLoS Negl Trop Dis. 2017; 11(2): e0005390.doi:10.1371/journal. pntd.0005390.
- Abate E, Belayneh M, Idh J, Diro E, Elias D, Britton S. et al. Asymptomatic helminth infection in active tuberculosis is associated with increased regulatory and Th-2 responses and a lower sputum smear positivity. PLoS Negl Trop Dis. 2015; 9(8): e0003994. 10.1371/journal.pntd.0003994.
- Potian JA, Rafi W, Bhatt K, McBride A, Gause WC, Salgame P. Preexisting helminth infection induces inhibition of innate pulmonary anti-tuberculosis defense by engaging the IL-4 receptor pathway. J Exp Med. 2011; 208: 1863±74. doi: 10.1084/jem.20091473.
Acknowledgments
We appreciate Dr. Padmini Salgame (Department of Medicine, Center for Emerging Pathogens, New Jersey Medical School, Rutgers—The State University of New Jersey, Newark, New Jersey, USA) for her suggestions in improving the quality of the manuscript.
References
- 1.
Sayre. 1999 April Pulley. Africa, twenty-first century books. ISBN 0-7613-1367-2.
- 2.
The 2013 Human Development Report–"The rise of the South: Human progress in a diverse world"". HDRO (Human Development Report Office) United Nations Development Programme. pp. 144–147.
- 3. Zumla A, Petersen E, Nyirenda T, Chakaya J. Tackling the tuberculosis epidemic in sub-Saharan Africa–unique opportunities arising from the second European Developing Countries Clinical Trials Partnership (EDCTP) programme 2015–2024. Int. J. Infect. Dis. 2015; 32: 46–49. pmid:25809755
- 4. Brooker S, Clements AC, Bundy DA. Global epidemiology, ecology and control of soil-transmitted helminth infections. Adv Parasitol.2006; 62: 221–261. pmid:16647972
- 5. Maizels RM, Balic A, Gomez-Escobar N, Nair M, Taylor MD, Allen JE. Helminth parasites–masters of regulation. Immunol. Rev. 2004; 201: 89–116. pmid:15361235
- 6.
World Health Organization Technical Report Series 2012. 972; Research priorities for helminth infections.
- 7. Hotez PJ, Kamath A. Neglected tropical diseases in sub-Saharan Africa: Review of their prevalence, distribution, and disease burden. PLoS Negl Trop Dis. 2009;3 (8): e412. pmid:19707588
- 8. Chan MS. 1997. The global burden of intestinal nematode infections—fifty years on. Parasitol Today. 13: 438–443. pmid:15275146
- 9. Bethony J, Brooker S, Albonico M, Geiger SM, Loukas A, Diemert D, et al. Soil-transmitted helminth infections: Ascariasis, trichuriasis, and hookworm. Lancet. 2006; 367: 1521–1532. pmid:16679166
- 10. Steinmann P, Keiser J, Bos R, Tanner M, Utzinger J. Schistosomiasis and water resources development: systemic review, meta-analysis, and estimates of people at risk. Lancet Infect Dis. 2006; 6: 411–425. pmid:16790382
- 11. de Silva NR, Brooker S, Hotez PJ, Montresor A, Engels D, Savioli L. Soil transmitted helminth infections: updating the global picture. Trends Parasitol. 2003; 19(12): 547–551. pmid:14642761
- 12. Cappello M. Global health impact of soil-transmitted nematodes. Pediatr Infect Dis J. 2004; 23:663–664. pmid:15247606
- 13.
Global distribution of helminth infection with their co-infections, 2011. [cited 2013 Mar]. http://www.who.int/neglected_diseases/preventive_chemotherapy/databank/en/index.html.
- 14. Zerdo Z, Yohanes T, Tariku B. Soil-transmitted helminth reinfection and associated risk factors among school age children in Chencha district, Southern Ethiopia: across sectional study. J. Parasitol. Res. 2016; Article ID 4737891. http://dx.doi.org/10.1155/2016/4737891.
- 15.
World Health Organization. 2004, World Health Report 2004 –changing history. Burden of disease in DALYs by cause, sex and mortality stratum in WHO regions, estimates for 2002. Geneva: WHO. Annex Table 3: 126–131.
- 16. Koroma JB, Sesay S, Conteh A, Koudou B, Paye J, Bah M, et al. Impact of five annual rounds of mass drug administration with ivermectin on onchocerciasis in Sierra Leone. Infect Dis Poverty. 2018;7(1):30. pmid:29628019
- 17. Griswold E, Eigege A, Ityonzughul C, Emukah E, Miri ES, Anagbogu I, et al. Evaluation of Treatment Coverage and Enhanced Mass Drug Administration for Onchocerciasis and Lymphatic Filariasis in Five Local Government Areas Treating Twice Per Year in Edo State, Nigeria. Am. J. Trop. Med. Hyg. 2018; pmid:29943709
- 18. Mmbando BP, Suykerbuyk P, Mnacho M, Kakorozya A, Matuja W, Hendy A, et al. High prevalence of epilepsy in two rural onchocerciasis endemic villages in the Mahenge area, Tanzania, after 20 years of community directed treatment with ivermectin. Infect Dis Poverty. 2018;7(1):64. pmid:29921319
- 19. Jia T-W, Melville S, Utzinger J, King CH, Zhou X-N. Soil-transmitted helminth reinfection after drug treatment: a systematic review and meta-analysis. PLoS Negl Trop Dis. 2012; 6(5), e1621. pmid:22590656
- 20. Keenan JD, Hotez PJ, Amza A, Stoller NE, Gaynor BD, Porco TC, Lietman TM. Elimination and eradication of neglected tropical diseases with mass drug administrations: a survey of experts. PLoS Negl Trop Dis. 2013; 7(12), e2562. pmid:24340111
- 21. Alemu G, Mama M. Intestinal helminth co-infection and associated factors among tuberculosis patients in Arba Minch, Ethiopia. BMC Inf Dis. 2017; 17:68 pmid:28086814
- 22. Torgerson PR, Devleesschauwer B, Praet N, Speybroeck N, Willingham AL, Kasugo F, Rokni MB, Zhou X-N, Fevre EM, Scripa B, Gargouri N, Furst T, Budke CM, Carabin H, Kirk MD, Angulo FJ, Havelaar A, de Silva N. World Heath Organisation estimates of the global and regional disease burden of 11 foodborne parasitic diseases, 2010: a data synthesis. PLoS Med. 2015; pmid:26633705
- 23.
World Health Organization Global Tuberculosis Report 2017. [cited 2017 Oct]. http://www.who.int/tb/publications/global_report/MainText_13Nov2017.pdf.
- 24.
World Health Organization Global tuberculosis report 2016. [cited 2017 Nov]. http://apps.who.int/medicinedocs/documents/s23098en/s23098en.pdf.
- 25. Comstock GW, Livesay VT, Woolpert SF. 1974. The prognosis of a positive tuberculin reaction in childhood and adolescence. Am J. Epidem. 99: 131–138.
- 26.
Estimated global TB incidence rates, WHO 2016. [cited 2017 Oct]. http://www.who.int/tb/publications/global_report/gtbr2017_main_text.pdf.
- 27. Trunz BB, Fine P, Dye C. Effect of BCG vaccination on childhood tuberculous meningitis and military tuberculosis worldwide: a meta-analysis and assessment of cost-effectiveness. Lancet.2006; 367:1173–1180. pmid:16616560
- 28. Anonymous. WHO declares tuberculosis a global emergency. Soz Preventivmed. 1993; 38:251–252
- 29. Dye C, Williams BG. Eliminating human tuberculosis in the twenty-first century. J R Soc Interface. 2008; 5: 653–662. pmid:17690054
- 30. Queval CJ, Brosch R and Simeone R. The Macrophage: A Disputed Fortress in the Battle against Mycobacterium tuberculosis. Front. Microbiol. 2017; 8:2284. pmid:29218036
- 31. Kaufmann SH. How can immunology contribute to the control of tuberculosis? Nat Rev. Immunol. 2001; 1:20–30 pmid:11905811
- 32. Jamwal SV, Mehrotra P, Singh A, Siddiqui Z, Basu A, Rao KVS. Mycobacterial escape from macrophage phagosomes to the cytoplasm represents an alternate adaptation mechanism. Scientific Reports. 2016; 6: 23089; pmid:26980157
- 33. Blomgran R, Ernst JD. Lung neutrophils facilitate activation of naive antigen specific CD4+ T cells during Mycobacterium tuberculosis infection. J. Immunol. 2011; 186:7110–7119. pmid:21555529
- 34. Paige C, Bishai WR. Penitentiary or penthouse condo: the tuberculous granuloma from the microbe’s point of view. Cell Microbiol. 2010; 12:301–309. pmid:20039878
- 35. Nandi B, Behar SM. Regulation of neutrophils by interferon-gamma limits lung inflammation during tuberculosis infection. J Exp Med. 2011; 208:2251–2262. pmid:21967766
- 36. Li L, Qiao D, Fu X, Lao S, Zhang X, Wu C. Identification of Mycobacterium tuberculosis-specific–, Th17 and Th22 cells using the expression of CD40L in tuberculous pleurisy. PLoS ONE. 2011; 6: e20165 pmid:21625607
- 37. Chen Q, Ghilardi N, Wang H, Baker T, Xie MH, et al. Development of Th1-type immune responses requires the type I cytokine receptor TCCR. Nature. 2000; 407:916–920 and 1,2 pmid:11057672
- 38. Domingo-Gonzalez R, Prince O, Cooper A, Khader S. Cytokines and chemokines in Mycobacterium tuberculosis infection. Microbiol Spectrum. 2016;.4(5):TBTB2-0018-2016. pmid:27763255
- 39. Keller C, Hoffmann R, Lang R, Brandau S, Hermann C, Ehlers S. Genetically determined susceptibility to tuberculosis in mice causally involves accelerated and enhanced recruitment of granulocytes. Infect Immun.2006; 74:4295–4309 pmid:16790804
- 40. Eruslanov EB, Lyadova IV, Kondratieva TK, Majorov KB, Scheglov IV, Orlova MO. Neutrophil responses to Mycobacterium tuberculosis infection in genetically susceptible and resistant mice. Infect Immun. 2005. 73:1744–1753. pmid:15731075
- 41. Cooper AM, Dalton DK, Stewart TA, Griffin JP, Russell DG. Disseminated tuberculosis in interferon gamma gene-disrupted mice. J Exp Med.1993. 178:2243–2247. pmid:8245795
- 42. Ottenhof TH, Kumararatne D, Casanova JL. Novel human immunodeficiencies reveal the essential role of type-1 cytokines in immunity to intracellular bacteria. Immunol. Today. 1998; 19:491–494 pmid:9818540
- 43. Mattila JT, OjoOO Kepka-Lenhart D, Marino S, Kim JE, Eum SY. Microenvironments in Tuberculous Granulomas Are Delineated by Distinct Populations of Macrophage Subsets and Expression of Nitric Oxide Synthase and Arginase Isoforms. The Journal of Immunology. 2013.
- 44. Duque-Correa MA, Kühl AA, Rodriguez PC, Zedler U, Schommer-Leitner S, Rao M. Macrophage arginase-1 controls bacterial growth and pathology in hypoxic tuberculosis granulomas. PNAS. 2014; E4024–E4032. pmid:25201986
- 45. Fabri M1, Stenger S, Shin DM, Yuk JM, Liu PT, Realegeno S. Vitamin D is required for IFN-gamma-mediated antimicrobial activity of human macrophages. Sci. Transl. Med. Oct. 2011. 12;3(104):104ra102. pmid:21998409
- 46. Allen JE, Maizels RM. Diversity and dialogue in immunity to helminths. Nat Rev Immunol. 2011; 11:375–388. pmid:21610741
- 47. Babu S, Blauvelt CP, Kumaraswami V, Nutman TB. Regulatory networks induced by live parasites impair both Th1 and Th2 pathways in patent lymphatic filariasis: implications for parasite persistence. J Immunol. 2006; 176:3248–3256. pmid:16493086
- 48. Satoguina J, Mempel M, Larbi J, Badusche M, Loliger C, Adjei O. Antigen specific T regulatory-1 cells are associated with immunosuppression in a chronic helminth infection (onchocerciasis). Microbes and Infection. 2002; 4:1291–1300. pmid:12443893
- 49. King CL, Mahanty S, Kumaraswami V. Cytokine control of parasite-specific anergy in human lymphatic filariasis: preferential induction of a regulatory T helper 2 lymphocyte subset. J Clin Invest 1993; 92:1667–1673. pmid:8408619
- 50. Gillan V, Devaney E. Regulatory T cells modulate Th2 responses induced by Brugia pahangi third-stage larvae. Infect Immun. 2005; 73: 4034–4042. pmid:15972491
- 51. Shevach EM, McHugh RS, Piccirillo CA, Thornton AM. Control of T-cell activation by CD4+ CD25+ suppressor T cells. Imm Rev.2001; 182: 58–67.
- 52. Oldenhove G, de Heusch M, Urbain-Vansanten G, Urbain J, Maliszewski C, Leo O, et al. CD4 CD25 regulatory T cells control T helper type 1 responses to foreign antigens induced by mature dendritic cells in vivo. J Exp Med. 2003; 198:259–266. pmid:12874259
- 53. Turner JD, Jackson JA, Faulkner H, Behnke J, Else KJ, Kamgno J. Intensity of intestinal infection with multiple worm species is related to regulatory cytokine output and immune hyporesponsiveness. J Infect Dis. 2008; 197:1204–1212. pmid:18462167
- 54. Rook GA. Th2 cytokines in susceptibility to tuberculosis. Curr. MolMed. 2007; 7:327–337.
- 55. Redford PS, Murray PJ, O’Garra A. The role of IL-10 in immune regulation during M. tuberculosis infection. Mucosal Immunol. 2011; 4:261–270. pmid:21451501
- 56. Ribeiro-Rodrigues R, Resende Co T, Rojas R. A role for CD4+CD25+ T cells in regulation of the immune response during human tuberculosis. Clin Exp Immunol. 2006; 144:25–34. pmid:16542361
- 57. Salgado E, Gómez-Reino JJ. The risk of tuberculosis in patients treated with TNF antagonists. Expert Rev. Clin. Immunol. 2011; 7: 329–340.
- 58. George PJ, Anuradha R, Kumaran PP, Chandrasekaran V, Nutman TB, Babu S. Modulation of mycobacterial-specific Th1 and Th17 cells in latent tuberculosis by coincident hookworm infection. J. Immunol. 2013; 190:5161–5168. pmid:23576678
- 59. Babu S, Bhat SQ, Kumar NP, Jayantasri S, Rukmani S, Kumaran P et al. Human type 1 and 17 responses in latent tuberculosis are modulated by coincident filarial infection through cytotoxic T lymphocyte antigen–4 and programmed death–1. J Infect Dis. 2009a; 200:288–298.
- 60. Babu S, Bhat SQ, Kumar NP, Anuradha R, Kumaran P, Gopi GP et al. Attenuation of toll-like receptor expression and function in latent tuberculosis by coexistent filarial infection with restoration following antifilarial chemotherapy. PLoS Negl Trop Dis.2009b; 3: e489.
- 61. Steel C, Nutman TB. CTLA-4 in filarial infections: implications for a role in diminished T cell reactivity. J Immunol. 2003; 170:1930–1938. pmid:12574361
- 62. Elias D, Mengistu G, Akuffo H, Britton S. Are intestinal helminths risk factors for developing active tuberculosis? Trop. Med. Int. Health, 2006 Apr;11 (4):551–8. pmid:16553939
- 63. Chatterjee S, Kolappan C, Subramani 2, Gopi PG, Chandrasekaran V, Fay MP, Babu S, Kumaraswami V, Nutman TB. Incidence of active pulmonary tuberculosis in patients with coincident filarial and/or intestinal helminth infections followed longitudinally in South India PLoS ONE 2014 Apr 11;9(4):e94603. eCollection 2014 pmid:24728010
- 64. Hubner MP, Killoran KE, Rajnik M, Wilson S, Yim KC, Torrero MN, et al. Chronic helminth infection does not exacerbate Mycobacterium tuberculosis infection. PLoS Negl Trop Dis. 2012; 6:e1970. pmid:23285308
- 65. Aranzamendi C, Sofronic-Milosavljevic L and Pinelli E. Helminths: immunoregulation and inflammatory diseases—which side are Trichinella spp. and Toxocara spp. on? J Parasitol Res. 2013. http://dx.doi.org/10.1155/2013/329438.
- 66.
Fine PEM. Immunities in and to tuberculosis: implications for pathogenesis and vaccination. In Porter JDH, McAdam PWJ (eds), Tuberculosis back to the future. Chichester: John Wiley & Sons Canada Ltd; 1994. p 53–80.
- 67.
Bloom BR, Fine PEM. The BCG experience: implications for future vaccine against tuberculosis. In Bloom BR (ed), Tuberculosis: pathogenesis, protection and control. Washington, DC: American Society of Microbiology; 1994. p 531–537.
- 68. Orme IM. The Achilles heel of BCG. Tuberculosis (Edinb). 2010; 90: 329–332 pmid:20659816
- 69. Adkins B, Leclerc C, Marshall-Clarke S. Neonatal adaptive immunity comes of age. Nat Rev Immunol. 2004; 4(7):553–564. pmid:15229474
- 70. Levy O. 2007. Innate immunity of the newborn: basic mechanisms and clinical correlates. Nat Rev Immunol. 2007 May;7(5):379–90. pmid:17457344
- 71. Smart JM, Kemp AS. Ontogeny of T-helper 1 and T-helper 2 cytokine production in childhood. Pediatr Allergy Immunol. 2001; 12: 181–187. pmid:11555314
- 72. Marchant A, Goetghebuer T, Ota MO, Wolfe I, Ceesay SJ, De Groote D. Newborns develop a Th1-type immune response to Mycobacterium bovis bacillus Calmette-Guérin vaccination. J Immunol. 1999; 163 (4):2249–55. pmid:10438968
- 73. Soares AP, Scriba TJ, Joseph S, Harbacheuski R, Murray RA, Gelderbloem SJ. Bacillus Calmette-Guérin vaccination of human newborns induces T cells with complex cytokine and phenotypic profiles. J Immunol. 2008; 180(5):3569–77. pmid:18292584
- 74. Lalor MK, Smith SG, Floyd S, Gorak-Stolinska P, Weir RE, Blitz R, et al. Complex cytokine profiles induced by BCG vaccination in UK infants. Vaccine. 2010; 28 (2010) 1635–1641
- 75. Elias D, Akuffo H, Pawlowski A, Haile M, Schon T, Britton S.(2004a). Schistosoma mansoni infection reduces the protective efficacy of BCG vaccination against virulent Mycobacterium tuberculosis. Vaccine 23 (2005) 1326–1334. pmid:15661380
- 76. Lalor MK, Floyd S, Gorak-Stolinska P, Ben-Smith A, Weir RE, Smith SG, et al. BCG vaccination induces different cytokine profiles following infant BCG vaccination in the UK and Malawi. J Infect Dis.2011; 204:1075–1085. pmid:21881123
- 77. Lalor MK, Ben-Smith A, Gorak-Stolinska P, Weir RE, Floyd S, Blitz R, et al. Population differences in immune responses to Bacille Calmette-Guérin vaccination in infancy. J Infect Dis. 2009; 199:795–800. pmid:19434928
- 78. Tameris M, Geldenhuys H, Luabeya AK, Smit E, Hughes JE, Vermaak S, et al. The candidate TB vaccine, MVA85A, induces highly durable Th1 responses. PLoS ONE. 2014; 9(2):e87340. pmid:24498312
- 79. Tameris MD, Hatherill M, Landry BS, Scriba TJ, Snowden MA, Lockhart S, et al. Safety and efficacy of MVA85A, a new tuberculosis vaccine, in infants previously vaccinated with BCG: a randomised, placebo-controlled phase 2b trial. The Lancet. 2013; 381(23–29): 1021–1028.
- 80. Wajja A, Kizito D, Nassanga B, Nalwoga A, Kabagenyi J, Kimuda S, et al. The effect of current Schistosoma mansoni infection on the immunogenicity of a candidate TB vaccine, MVA85A, in BCG-vaccinated adolescents: An open-label trial. PLoS Negl. Trop. Dis. 2017; 11(5):e0005440. pmid:28472067
- 81. Meeren OV, Hatherill M, Nduba V, Wilkinson RJ, Muyoyeta M, Van Brakel E, et al. Phase 2b placebo-controlled trial of M72/AS01E candidate vaccine to prevent active tuberculosis in adults. N. Engl. J. Med. 2018; pmid:30280651
- 82. Kilian HD, Nielsen G. Cell-mediated and humoral responses to BCG and rubella vaccinations and to recall antigens in onchocerciasis patients. Trop Med Parasitol. 1989; 40: 445–453. pmid:2623427
- 83. Elias D, Britton S, Aseffa A, Engers H, Akuffo H. Poor immunogenicity of BCG in helminth-infected population is associated with increased in vitro TBF-b production. Vaccine. 2008; 26: 3897–3902. pmid:18554755
- 84. Elias D, Wolday D, Akuffo H, Petros B, Bronner U, Britton S. Effect of deworming on human T cell responses to mycobacterial antigens in helminth-exposed individuals before and after BCG vaccination. Clin Exp Immunol. 2001; 123: 219–225. pmid:11207651
- 85. Malhotra I, Mungai P, Wamachi A, Kioko J, Ouma JH, Kazura JW. Helminth- and Bacillus Calmette-Guérin-induced immunity in children sensitized in utero to filariasis and schistosomiasis. J. Immunol. 1992; 162(11):6843–8.
- 86. Webb EL, Mawa PA, Ndibazza J, Kizito D, Namatovu A, Kyosiimire-Lugemwa J. et al. Effect of single-dose anthelmintic treatment during pregnancy on an infant’s response to immunisation, and on susceptibility to infectious disease in infancy: a randomised, double-blind, placebo-controlled trial. Lancet. 2011; 377: 52–62 pmid:21176950
- 87.
Bulletin of the World Health Organization, 1995, 73 (6): 805–806. WHO statement on BCG revaccination for the prevention of tuberculosis.
- 88. Nemes E, Geldenhuys H, Rozot V, Tucker Rutkowski K, Ratangee F, Bilek N, et al. Prevention of infection with Mycobacterium tuberculosis by H4:IC31® vaccination or BCG revaccination in adolescents. N. Engl. J. Med. 2018; 379: 138–149. pmid:29996082
- 89. Mangtani P, Abubakar I, Ariti C, Beynon R, Pimpin L, Fine PE. Protection by BCG vaccine against tuberculosis: a systematic review of randomized controlled trials. Clin Infect Dis.2014; 58(4):470–80. pmid:24336911
- 90. Wilson ME, Fineberg HV, Colditz GA. Geographic latitude and the efficacy of bacillus Calmette-Guérin vaccine. Clin. Infect. Dis. 1995; Apr;20(4):982–91. pmid:7795103
- 91. Stephenson LS, Latham MC, Ottesen EA. Malnutrition and parasitic helminth infections. Parasitol. 2000; 121 (Suppl): S23–S38.
- 92. Pelly TF, Santillan CF, Gilman RH, Cabrera LZ, Garcia E, Vidal C. Tuberculosis skin testing, energy and protein malnutrition in Peru. Int J Lung Dis.2005; 9: 977–984.
- 93. Moran-Mendoza O, Marion SA, Elwood K, Patrick D, FitzGerald JM. Risk factors for developing tuberculosis. Int J Tuberc Lung Dis. 2010; 14: 1112–1119. pmid:20819255
- 94. Kozak R, Behr MA. Divergence of immunologic and protective responses of different BCG strains in a murine model. Vaccine. 2011; 29: 1519–1526. pmid:21184855
- 95. Brosch R, Gordon SV, Garnier T, Eiglmeier K, Frigui W, Valenti P, et al. Genome plasticity of BCG and impact on vaccine efficacy. Proc Natl Acad Sci. 2007; 104: 5596–5601. pmid:17372194
- 96. Venkataswamy MM, Goldberg MF, Baena A, Chan J, Jacobs WR Jr, Porcelli SA. In vitro culture medium influences the vaccine efficacy of Mycobaterium bovis BCG. Vaccine. 2012; 30: 1038–1049. pmid:22189700
- 97. Stewart GR, Boussinesq M, Coulson T, Elson L, Nutman T, Bradley JE. Onchocerciasis modulates the immune response to mycobacterial antigens. Clin Exp Immunol. 1999; 117:517–523 pmid:10469056
- 98. Claridge J, Diggle P, McCann CM, Mulcahy G, Flynn R, McNair J. Fasciola hepatica is associated with failure to detect bovine tuberculosis in diary cattle., Nat. Commun. 2012; 3:853. pmid:22617293
- 99. Garza-Cuatero L, O’Sullivan J, Bianco A, McNair J, Welsh M, Flynn RJ, et al. Fasciola hepatica infection reduces Mycobacterium bovis burden and mycobacterial uptake and suppresses the pro-inflammatory response. Parasite Immunol., 2016; 38(7): 387–402. pmid:27108767
- 100. Mhimbira F, Hella J, Said K, Kamwela L, Sasamalo M, Maroa Tet al. Prevalence and clinical relevance of helminth co-infections among tuberculosis patients in urban Tanzania. PLoS Negl Trop Dis. 2017; 11(2):e0005342. pmid:28178325
- 101. Abate E, Belayneh M, Idh J, Diro E, Elias D, Britton S.et al. Asymptomatic helminth infection in active tuberculosis is associated with increased regulatory and Th-2 responses and a lower sputum smear positivity. PLoS Negl Trop Dis. 2015; 9(8): e0003994. pmid:26248316
- 102. Benyon F, Theron G, Respeito D, Mambuque E, Saavedra B, Bulo H. ET AL. Correlation of Xpert MTB/RIF with measures to assess Mycobacterium tuberculosis bacillary burden in high HIV burden areas of Southern Africa. Nature.com/scientificreports. 2018.
- 103. O’Shea MK, Flether T, Muller J, Tanner R, Matsumiya M, Bailey JW. Et al. Frontiers in Immunology, 2018; 9: article 2893.
- 104. 99. 100. Pai M, Denkinger CM, Kik SV, Rangaka MX, Zwerling A, Oxlade O. Gamma interferon release assays for detection of Mycobacterium tuberculosis infection. Clin Microbiol Rev.2014; 27:3–20. pmid:24396134
- 105. Moon HW, Hur M. Interferon-gamma release assays for the diagnosis of latent tuberculosis infection: an updated review. Ann Clin Lab Sci. 2013; 43: 221–229. pmid:23694799
- 106. Mahairas GG, Sabo PJ, Hickey MJ, Singh DC, Stover CK. Molecular analysis of genetic differences between Mycobacterium bovis BCG and virulent M. bovis. J Bacteriol. 1996; 178: 1274–1282. pmid:8631702
- 107. Thomas TA, Mondal D, Noor Z, Lui L, Alam M, Haque Ret al. Malnutrition and helminth infection affect performance of an interferon-gamma release assay. Pediatrics.2010; 126: e1522–e1529. pmid:21059723
- 108. Gebreegziabiher D, Desta K, Howe R, Abebe M. Helminth infection increases the probability of indeterminate QuantiFERON gold in tube results in pregnant women. Biomed Res Int. 2014; 364137. pmid:24701572
- 109. Anuradha R, Munisankar S., Bhootra Y, Dolla C, Kumaran P, Nutman TB, Babu S. Anthelmintic therapy modifies the systemic and mycobacterial antigen-stimulated cytokine profile in helminth-latent Mycobacterium tuberculosis co-infection. Infect. Immun. 2017. 85(4): e00973–16. pmid:28167672
- 110. Verhagen LM, Hermans PWM, Warris A, de Groot R, Maes M, Villalba JA. Et al., Helminths and skewed cytokine profiles increase tuberculin skin test positivity in Warao Amerindians. Tuberculosis, 2012, 92: 505–512. pmid:22877977
- 111. Lipner EM, Gopi PG, Subramani R, Kolappan C, Sadacharam K, Kumaran P. et al. Coincident filarial, intestinal helminth, and mycobacterial infection: helminths fail to influence tuberculin reactivity, but BCG influences hookworm prevalence. Am J Trop Med Hyg. 2006; 74: 841–847. pmid:16687690
- 112. Labeaud AD, Malhotra I, King MJ, King CL. King CH. Do antenatal parasite infections devalue childhood vaccination? PLoS Negl Trop Dis. 2009; 3: e442, pmid:19478847
- 113. Aira N, Andersson AM, Singh SK, McKay DM, Blomgran R. Species dependent impact of helminth-derived antigens on human macrophages infected with Mycobacterium tuberculosis: Direct effect on the innate antimycobacterial response. PLoS Negl Trop Dis. 2017; 11(2): e0005390. pmid:28192437
- 114. DiNardo AR, Nishiguchi T, Mace EM, Rajapakshe K, Mtetwa G, Kay A. et al. Schistosomiasis induces persistent DNA methylation and tuberculosis-specific immune changes. J. Immunol. 2018, 201(10: 124–133.
- 115. Elias D, Akuffo H, Thors C, Pawlowski A, Britton S. Low dose chronic Schistosoma mansoni infection increases susceptibility to Mycobacterium bovis BCG infection in mice. Clin Exp Immunol. 2005; 139: 398±404. pmid:15730384;
- 116. Potian JA, Rafi W, Bhatt K, McBride A, Gause WC, Salgame P. Preexisting helminth infection induces inhibition of innate pulmonary anti-tuberculosis defense by engaging the IL-4 receptor pathway. J Exp Med. 2011; 208: 1863±74. pmid:21825018;
- 117. Monin L, Griffiths KL, Lam WY, Gopal R, Kang DD, Ahmed M, et al. Helminth-induced arginase-1 exacerbates lung inflammation and disease severity in tuberculosis. J Clin Invest. 2015; 125: 4699±713. pmid:26571397.
- 118. du Plessis N, Kleynhans L, Thiart L, van Helden PD, Brombacher F, Horsnell WG, et al. Acute helminth infection enhances early macrophage mediated control of mycobacterial infection. Mucosal Immunol. 2013; 6: 931±41. pmid:23250274;
- 119. Nel HJ, du Plessis N, Kleynhans L, Loxton AG, van Helden PD, Walzl G. Mycobacterium bovis BCG infection severely delays Trichuris muris expulsion and co-infection suppresses immune responsiveness to both pathogens. BMC Microbiol. 2014; 14: 9. pmid:24433309;
- 120. Rafi W, Bhatt K, Gause WC, Salgame P. Neither primary nor memory immunity to Mycobacterium tuberculosis infection is compromised in mice with chronic enteric helminth infection. Infect Immun. 2015; 83: 1217±23. pmid:25605766;
- 121. Sakai S, Kauffman KD, Sallin MA, Sharpe AH, Young HA, Ganusov VV, et al. CD4 T cell-derived IFN-gamma plays a minimal role in control of pulmonary Mycobacterium tuberculosis infection and must be actively repressed by PD-1 to prevent lethal disease. PLoS Pathog. 2016; 12:e1005667. pmid:27244558
- 122. George PJ, Anuradha R, Kumar NP, Sridhar R, Banurekha VV, Nutman TB, Babu S. (2014) Helminth Infections Coincident with Active Pulmonary Tuberculosis Inhibit Mono- and Multifunctional CD4+ and CD8+ T Cell Responses in a Process Dependent on IL-10. PLoS Pathog. 10(9): e1004375. pmid:25211342
- 123. George PJ, Anuradha R, Kumaran PP, Chandrasekaran V, Nutman TB, Babu S. (2013). Modulation of Mycobacterial-Specific Th1 and Th17 Cells in Latent Tuberculosis by Coincident Hookworm Infection
- 124. Elias D, Akuffo H, Pawlowski A, Haile M, Schon T, Britton S.(2004a). Schistosoma mansoni infection reduces the protective efficacy of BCG vaccination against virulent Mycobacterium tuberculosis. Vaccine 23 (2005) 1326–1334. pmid:15661380
- 125. Frantz FG, Rosada RS, Peres-Buzalaf C, Perusso FRT, Rodrigues V, Ramos SG, Kunkel SL, Silva CL, Faccioli LH. (2010). Helminth Coinfection Does Not Affect Therapeutic Effect of a DNA Vaccine in Mice Harboring Tuberculosis. PLoS Negl Trop Dis. 4(6): e700. pmid:20544012
- 126. Elias D, Akuffo H, Thors C Pawlowski A, Britton S (2004b). Low dose chronic Schistosoma mansoni infection increases susceptibility to Mycobacterium bovis BCG infection in mice. Clinical and Experimental Immunology, 139:398–404
- 127. Flynn R.J, Mulcahy G, Welsh M, Cassidy JP, Corbett D, Milligan C, Andersen P, Strain S,.McNair J. (2009). Co-Infection of Cattle with Fasciola hepatica and Mycobacterium bovis–Immunological Consequences. Transboundary and Emerging Diseases. 56: 269–274. pmid:19575746
- 128. Flynn RJ, Mannion C, Golden O, Hacariz O, Mulcahy G. Experimental Fasciola hepatica infection alters responses to tests used for diagnosis of bovine tuberculosis. Infect Immun. 2007; 75 (3):1373–1381. pmid:17194810